{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yadav S"],"funding":["NCRR NIH HHS","U.S. Department of Defense","NIGMS NIH HHS"],"pagination":["873-80"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4537374"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(9)"],"pubmed_abstract":["DNA polymerase kappa is a Y-family polymerase that participates to bypass the damaged DNA known as translesion synthesis (TLS) polymerase. Higher frequency of mutations in DNA polymerase kappa (POLK) recently been reported in prostate cancer. We sequenced entire exons of the POLK gene on genomic DNA from 40 prostate cancers and matched normal samples. We identified that 28% of patients have somatic mutations in the POLK gene of the prostate tumors. Mutations in these prostate cancers have somatic mutation spectra, which are dominated by C-to-T transitions. In the current study, we further investigate the effect of p.E29K, p.G154E, p.F155S, p.E430K, p.L442F, and p.E449K mutations on the biochemical properties of the polymerase in vitro, using TLS assay and nucleotide incorporation fidelity,"],"journal":["Human mutation"],"pubmed_title":["Somatic Mutations in Catalytic Core of POLK Reported in Prostate Cancer Alter Translesion DNA Synthesis."],"pmcid":["PMC4537374"],"funding_grant_id":["P20 RR020152","PC094628","P20 GM103518"],"pubmed_authors":["Makridakis N","Anbalagan M","Yadav S","Mukhopadhyay S"],"additional_accession":[]},"is_claimable":false,"name":"Somatic Mutations in Catalytic Core of POLK Reported in Prostate Cancer Alter Translesion DNA Synthesis.","description":"DNA polymerase kappa is a Y-family polymerase that participates to bypass the damaged DNA known as translesion synthesis (TLS) polymerase. Higher frequency of mutations in DNA polymerase kappa (POLK) recently been reported in prostate cancer. We sequenced entire exons of the POLK gene on genomic DNA from 40 prostate cancers and matched normal samples. We identified that 28% of patients have somatic mutations in the POLK gene of the prostate tumors. Mutations in these prostate cancers have somatic mutation spectra, which are dominated by C-to-T transitions. In the current study, we further investigate the effect of p.E29K, p.G154E, p.F155S, p.E430K, p.L442F, and p.E449K mutations on the biochemical properties of the polymerase in vitro, using TLS assay and nucleotide incorporation fidelity,","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Sep","modification":"2026-05-30T04:28:28.765Z","creation":"2019-03-27T01:56:48Z"},"accession":"S-EPMC4537374","cross_references":{"pubmed":["26046662"],"doi":["10.1002/humu.22820"]}}